Influence of presurgical idiopathic hyperprolactinemia on relapse rate in operable breast cancer.
Cazzaniga
M
M
Lissoni
P
P
Ardizzoia
A
A
Tancini
G
G
Barni
S
S
D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001365:Axilla; D001943:Breast Neoplasms / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D006966:Hyperprolactinemia / Q000150:complications*; D008207:Lymphatic Metastasis; D008593:Menopause; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology* / Q000503:physiopathology; D010865:Pilot Projects; D011388:Prolactin / Q000097:blood; D011960:Receptors, Estrogen / Q000032:analysis; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D013629:Tamoxifen; D011388:Prolactin; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate